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Summary
Background Unless women start effective contraception after oral emergency contraception, they remain at risk of 
unintended pregnancy. Most women in the UK obtain emergency contraception from community pharmacies. We 
hypothesised that pharmacist provision of the progestogen-only pill as a bridging interim method of contraception 
with emergency contraception plus an invitation to a sexual and reproductive health clinic, in which all methods of 
contraception are available, would result in increased subsequent use of effective contraception.
Methods We did a pragmatic cluster-randomised crossover trial in 29 UK pharmacies among women receiving 
levonorgestrel emergency contraception. Women aged 16 years or older, not already using hormonal contraception, 
not on medication that could interfere with the progestogen-only pill, and willing to give contact details for follow-up 
were invited to participate. In the intervention group, women received a 3-month supply of the progestogen-only pill 
(75 μg desogestrel) plus a rapid access card to a participating sexual and reproductive health clinic. In the control 
group, pharmacists advised women to attend their usual contraceptive provider. The order in which each pharmacy 
provided the intervention or control was randomly assigned using a computer software algorithm. The primary 
outcome was the use of effective contraception (hormonal or intrauterine) at 4 months. This study is registered, 
ISRCTN70616901 (complete).
Findings Between Dec 19, 2017, and June 26, 2019, 636 women were recruited to the intervention group 
(316 [49·6%], mean age 22·7 years [SD 5·7]) or the control group (320 [50·3%], 22·6 years [5·1]). Three women (one 
in the intervention group and two in the control group) were excluded after randomisation. 4-month follow-up data 
were available for 406 (64%) participants, 25 were lost to follow-up, and two participants no longer wanted to participate 
in the study. The proportion of women using effective contraception was 20·1% greater (95% CI 5·2–35·0) in the 
intervention group (mean 58·4%, 48·6–68·2), than in the control group (mean 40·5%, 29·7–51·3 [adjusted for 
recruitment period, treatment group, and centre]; p=0·011).The difference remained significant after adjusting for age, 
current sexual relationship, and history of effective contraception use, and was robust to the effect of missing data 
(assuming missingness at random). No serious adverse events occurred.
Interpretation Provision of a supply of the progestogen-only pill with emergency contraception from a community 
pharmacist, along with an invitation to a sexual and reproductive health clinic, results in a clinically meaningful 
increase in subsequent use of effective contraception. Widely implemented, this practice could prevent unintended 
pregnancies after use of emergency contraception.
Funding National Institute for Health Research (Health Technology Assessment Programme project 15/113/01).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Emergency contraception prevents unintended pregnancy 
after unprotected sex or contraceptive failure,1 but unless 
women start an effective method of ongoing contraception 
after oral emergency contraception, they remain at risk of 
unintended pregnancy. Women who have unprotected 
sex after receiving emergency contra ception (in the same 
cycle) are up to three-times more likely to conceive than 
women who do not,1–3 and without contraception these 
women remain at risk of pregnancy in subsequent cycles. 
Current UK and US guidelines recommend initiating 
regular hormonal contraception immediately after emer-
gency contraception (known as quick-starting).4,5
In the UK, as in many other countries, most women 
obtain emergency contraception from community phar-
macies without a prescription.6 However, for ongoing 
contraception, pharmacists can generally only provide 
barrier methods which have high failure rates.7 With 
the exception of a few areas in the UK in which local 
arrangements have been made for a finite supply of oral 
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contraceptives from the pharmacist,8 most women need 
to attend a contraceptive provider such as their general 
practitioner or a sexual and reproductive health clinic, 
which takes time and women might lose motivation to 
seek contraception and the risk for unintended preg-
nancy increases.
In 2012, we did a pilot study among 168 women 
presenting to 11 community pharmacies in Edinburgh 
(UK) for levonorgestrel-containing emergency contra-
ception. Pharmacies offered a 1-month supply of a 
progestogen-only pill, or an invitation for rapid access 
to a sexual and reproductive health clinic for advice 
and provision of ongoing contra ception, or standard 
advice about starting contraception after emergency 
contraception.9 When participants were followed up 
6–8 weeks later, the proportion of women using effective 
contraception was significantly greater in both the 
progestogen-only pill group (22 [56%] of 39 women; 
p=0·001) and the rapid access group (13 [52%] of 25; 
p=0·006) compared with standard care (5 [16%] of 31).
Here, we present the findings of the full trial designed 
to support the findings of the pilot study. We used a 
composite intervention of a bridging supply of the 
progestogen-only pill and the offer of rapid access to a 
participating sexual and reproductive health clinic. This 
approach combined temporary contraception (giving 
women time to get an appointment with their usual 
contraceptive provider) with facilitated access to a 
specialist contraceptive service in which all methods of 
contraception, including the most effective methods 
of long-acting reversible contraception (LARC), were 
available. The aim of this study was to determine 
whether the composite intervention resulted in increased 
use of subsequent effective contraception (hormonal or 
intrauterine) compared with provision of emergency 
contraception alone.
Methods
Study design and participants
Bridge-It was a cluster-randomised cohort crossover trial 
including 29 pharmacies in three UK regions: London 
(south and central), Lothian (Edinburgh and region), and 
Tayside (Dundee and region).10 The order in which each 
pharmacy provided the intervention or control was 
randomly assigned, with an intervening period of at least 
2 weeks (during which recruitment was halted). Each 
pharmacy recruited women into the intervention and 
the control cohorts. We chose cluster design because the 
pilot study9 showed that randomisation of individual 
participants (rather than pharmacies), would not recruit 
enough participants. The crossover design was chosen for 
efficiency so that each cluster was acting as its own control 
and fewer pharmacies were required. The washout period 
(planned duration of at least 2 weeks) between recruitment 
periods minimised the effect of the preceding intervention 
or control.10 Study pharmacies were chosen on the basis of 
their geographical position (within 5 miles of the sexual 
and reproductive health study clinics), the volume of 
emer gency contraception dispensed (more than 30 each 
month), and the presence of a private interview area.
Research in context
Evidence before this study
We searched PubMed for articles in English published from 
March 1, 2000, to March 30, 2020, using the search terms 
“bridging” OR “bridge” AND “emergency contracept”. We found 
12 articles of which only two were relevant. One article was a 
cluster-randomised pilot study, done by the authors of this 
study, of 11 pharmacies in Edinburgh (UK) supplying 1 month of 
the progestogen-only pill plus emergency contraception, or an 
offer of rapid access to a local sexual and reproductive health 
clinic (upon presentation of a card to the clinic) where 
contraception would be supplied, or emergency contraception 
alone (control). In both intervention groups a significantly 
higher proportion of women (more than double) were using 
regular effective contraception after 6–8 weeks compared with 
the group receiving emergency contraception alone. The other 
article was a cluster-randomised trial in Jamaica and offered 
women seeking emergency contraception a discount voucher 
for a limited period (voucher had to be used within 2·5 to 
4 months of recruitment) on the subsequent cost of 
contraceptive pills. This study reported no effect of the 
intervention on contraceptive use. The scarcity of data on this 
topic underlined the need for a high quality, adequately 
powered, randomised trial.
Added value of this study
Our study showed that pharmacy provision of a 3-month 
supply of progestogen-only pill and the offer of rapid access to 
a sexual and reproductive health clinic along with emergency 
contraception was associated with a 20% increase in use of 
effective contraception 4 months later (1 month after 
progestogen-only pill had run out) compared with provision of 
emergency contraception alone.
Implications of all the available evidence
Most women who use emergency contraception remain at risk 
of unintended pregnancy unless they start an effective method 
of contraception. The progestogen-only pill is a safe 
contraceptive with few contraindications, low cost, and high 
suitability for provision from the community pharmacy. 
An increase of 20% in effective contraceptive uptake was large 
and clinically significant. Offering a 3-month supply of 
progestogen-only pill and rapid access to a contraceptive 
service with emergency contraception might prevent many 
more unintended pregnancies if this practice became standard 
practice in UK pharmacies.
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Participants were women receiving emergency contra-
ception from a study pharmacy. The emergency contra-
ception used in the study was levonorgestrel, given in 
the clinically indicated dose (1·5 mg or 3 mg) according 
to bodyweight.4 In the intervention group, women 
received three packets of the progestogen-only pill 
containing 28 tablets (75 μg desogestrel per day) at no 
cost. Locally approved Patient Group Directions (strict 
criteria to permit provision of specified medicines by 
non-pre scribers) allowed pharmacists to dispense the 
proges togen-only pill to participants. Women aged 
16 years or older, not already using hormonal contra-
ception, not on medication that could interfere with the 
progestogen-only pill, and willing to give contact details 
for follow-up were invited to participate. Full inclusion 
and exclusion criteria are described in the appendix (p 1).11 
Pre-study training for pharmacists was delivered using 
the study protocol and Patient Group Directions for the 
progestogen-only pill, which included information about 
medical contra indications, potential drug interactions, 
and missed pill guidance. Pharmacists were instructed 
to advise women to start the progestogen-only pill the 
day after emergency contraception. As part of the inter-
vention, women also received a rapid access card that 
upon presentation to the local participating sexual and 
reproductive health clinic enabled them to discuss and 
obtain alternative effective contraception, including 
LARC. The card provided infor mation about the location 
and opening hours of the sexual and reproductive 
health clinic, which provided consultations and all 
methods of contraception at no cost, as is the norm in 
the UK National Health Service (NHS). In the control 
group, women received standard care (emergency 
contraception and advice about ongoing contraception). 
Mystery shopper visits were done just before control 
group recruitment started to document the content of 
standard care consultations on emergency contraception 
and these data have been published.12
A multi-method process evaluation was also conducted 
to assess implementation, mechanisms of change, and 
context,10 and included qualitative interviews with partici-
pants, pharmacists, and staff at sexual and reproductive 
health clinics (findings will be reported separately).
Pharmacists assessed women’s eligibility for the study 
(appendix p 2), invited them to participate, and obtained 
written informed consent for the study (including access 
to sexual and reproductive health records and data 
linkage with the national abortion registries). Pharmacists 
also provided a patient information sheet. Participants 
completed a baseline questionnaire that included demo-
graphic details, reproductive history, and previous 
methods of contraception used including emergency 
contraception. To maximise retention in the study, 
participants received an incentive voucher of £10 at 
recruitment.13 Pharmacies received £30 per participant 
enrolled onto the study to cover costs of the time spent 
recruiting participants. Ethical approval was obtained 
from the South East Scotland Research Ethics Committee 
in June, 2017. Approvals were also obtained from NHS 
Research Scotland and the Health Research Authority 
in England. The full study protocol is available in the 
paper published in 2019, by Cameron and colleagues.10
Randomisation and masking
Eligible participants who met the criteria were enrolled to 
receive the progestogen-only pill plus a rapid access card 
to a sexual and reproductive health clinic (intervention 
group) or received advice from a pharmacist to attend 
their usual contraceptive provider (control group). The 
order in which pharmacies delivered the control or 
intervention was randomised for each pharmacy, and 
generated using a computer software algorithm that 
randomly allocated permuted blocks of size 2, 4, and 6; 
blocking was used to ensure a balanced order. The 
randomisation file was prepared by a study statistician at 
the Centre for Healthcare Randomised Trials (University 
of Aberdeen, UK), using SAS version 6.4. The study 
statistician was masked to the outcome assessment, 
but women and research nurses were not masked. 
Pharmacists were informed of the randomised allocation 
by the study trial manager at the Edinburgh Clinical Trials 
Unit. 
Procedures
Participants in both groups had a single follow-up at 
4 months through a telephone interview with a research 
nurse or a self-administered online questionnaire. The 
follow-up method was chosen according to participants’ 
preference. Participants who did not respond to three 
attempts to contact them by telephone or email were 
considered lost to follow-up. In addition to contraceptive 
use, women were asked about their interaction with 
the pharmacist and use of the rapid access card (inter-
ven tion group only). Partici pants reporting pregnancy 
also completed the London Measure of Unplanned 
Pregnancy questionnaire—validated to measure the 
intendedness of pregnancy.14,15 Only serious adverse 
events were recorded from start of recruitment to the 
4-month follow-up. Other adverse events were not 
recorded because both the emergency contraception 
and progestogen-only pill are approved medicines used 
for licensed indications. The participating sexual and 
reproductive health clinics also searched records for data 
on whether, and for what reason, participants in both 
groups had used their service during the 4 months 
following recruitment.
Outcomes
The primary outcome was self-reported use of effective 
contraception (hormonal or intrauterine) at 4 months. 
Secondary outcomes were incidence of abortion in the 
12 months following recruitment and an economic 
evaluation of the intervention. Both secondary outcomes 
will be reported separately. A post-hoc analysis was also 
See Online for appendix
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done, adjusting (in addition to the prespecified baseline 
covariates) for ethnicity and having given birth.
Statistical analysis
The original power calculation was based on two 
coprimary outcomes; abortion rates at 12 months after 
recruitment and effective contraception use at 4 months 
follow-up. The abortion outcome at 12 months required 
over 2000 women to be enrolled in more than 
26 pharmacies to have 90% power at 2·5% level of 
significance to detect a relative reduction in the abortion 
rate of around 50%—eg, from 8% to 4%. Recruiting this 
large number of women was not fea sible within the 
available timeframe and resources. Without seeing the 
unblinded data, the independent oversight com mittees 
(Trial Steering Committee and Data Monitoring 
Committee) and the funder (National Institute for Health 
Research [Health Technology Assessment Programme]) 
agreed to repower the study on a single coprimary 
outcome (effective contraceptive use at 4 months) to have 
90% power at 5% level of significance to show an increase 
in effective contraception use from around 30% to 45% 
(absolute change 15%, relative increase 50%). For this 
outcome, the study required between 626 and 737 women, 
depending on the intraclass correlations (within cluster-
periods and between cluster-periods), which could not be 
observed within the study at the time this change was 
made.16 This calculation assumed that 25% of women 
would be missing the outcome (lost to follow-up) at 
4 months and that 25 pharmacies would be participating.
The baseline characteristics and 4-month follow-up 
data were summarised using mean (SD) or median (IQR) 
for continuous variables. Discrete variables were sum-
marised with numbers and percentages. Analyses were 
done on the intention to treat principle. For the primary 
outcome, the percentage of women reporting effective 
contraception use in each cluster-period was analysed 
using linear regression adjusting for period, treat-
ment group, and centre.17 The published study protocol10 
specified a hierarchical mixed effect, logistic regression 
on individual data for the analysis of effective contra-
ception use at 4 months. We revised this analysis in the 
final Statistical Analysis Plan (accepted Nov 5, 2019, 
before any unblinded data had been seen) to use a linear 
model on the unweighted proportion (expressed as a 
percentage), with the same primary outcome at site 
level, following methodological guidance from Morgan 
and colleagues,17 and we used the hierarchical mixed 
effects logistic regression as a sensitivity type analysis. 
Although the linear model on percentages at site level 
makes less use of the available information, it can be 
more robust, with fewer assumptions, and expresses the 
treatment effect as a percentage difference in proportion 
rather than an odds ratio.
Prespecified baseline covariates (mean age, 
percentage of participants who were in an ongoing 
sexual relation ship, and percentage of participants who 
had used effec tive contraception methods previously) 
were included in an additional analysis. A two-sided 
p value of <0·05 was taken as statistically significant. 
For the primary outcome, pre specified subgroup 
analysis was done for LARC use according to the 
classification by the UK National Institute for Health 
and Care Excellence (intrauterine contraception, 
implant, injectable)18 with a more strin gent definition 
of statistical significance (two-sided 1% sig nificance 
level with 99% CI). Sensitivities of treatment effect 
estimate for missing outcome data was analysed using 
multiple imputation. All analyses were done with 
STATA (version 16). An independent data monitoring 
committee oversaw the study. The trial registry number 
is ISRCTN70616901.Figure 1: Trial profile
32 pharmacies were randomised 
29 pharmacies recruited participants
2 weeks washout phase 
13 allocated to standard treatment 
13 received allocated intervention (12·38 average
cluster size, 107·42 variance of  cluster sizes)
16 allocated to bridging contraception
16 received allocated intervention (14·38 average
cluster size, 112·12 variance of cluster sizes)
3 did not recruit any participants
56 pharmacies assessed for eligibility 
24 pharmacies excluded
 8 not eligible 
 8 declined to participate
 8 did not respond 
21 analysed 
Bridging contraception: 
(13·86 average cluster size, 104·43 variance of cluster sizes)
Standard treatment: 
(13·48 average cluster size, 119·96 variance of cluster sizes)  
8 excluded from analysis (7·50 average cluster size, 23·71 variance 
of cluster sizes) 
4 did not have outcomes in one of the phases
4 did not recruit in one of the phases
16 allocated to standard treatment
14 received allocated intervention (11·36 average 
cluster size, 113·17 variance of cluster sizes)
2 did not receive allocated intervention 
(pharmacy did not recruit) 
13 allocated to bridging contraception
11 received allocated intervention (7·82 average 
cluster size, 67·76 variance of cluster sizes)
2 did not receive allocated intervention 
(pharmacy did not recruit)
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Of 56 pharmacies approached, 32 agreed to take part 
and between Dec 19, 2017, and June 26, 2019, 29 phar-
macies were recruited (14 pharmacies in London, 12 in 
Edinburgh, and three in Tayside; figure 1). The change to 
include only a single primary outcome took place in 
January, 2019. A total of 1252 participants were screened; 
762 were eligible, and 636 participants gave consent and 
were enrolled. Three women (one in the intervention 
group and two in the control group) were excluded after 
randomisation. The trial profile of participants is shown 
in figure 2. The median number of participants recruited 
in each pharmacy was 17 (range 2–73). The number of 
participants recruited in each period of the study for 
each pharmacy ranged from two to 35 in phase 1 of 
recruitment and from 0 to 38 in period 2 of recruitment. 
Reasons for ineligibility are shown in the appendix (p 2).
Baseline characteristics of participants by randomised 
group and study period are summarised in table 1. The 
mean age of participants was 22·7 years (SD 5·7) in the 
intervention group and 22·6 years (5·1) in the control 
group. Follow-up data at 4 months were available for 
198 (63%) of 315 women in the interven tion group and 
208 (65%) of 318 in the control group. Follow-up rates did 
not differ statistically between study groups or between 
those recruited in period 1 or period 2. There were no 
differences between responders and non-responders in 
any baseline characteristics (appendix p 3). No serious 
adverse events were reported in either group.
The proportion of women reporting use of effective 
contraception (hormonal and intrauterine; table 2) after 
adjustment was 20·1% higher (95% CI 5·2–35·0; p=0·011) 
in the intervention group (58·4%, SD 21·6) than in the 
control group (40·5%, 23·8). Effective contraception use 
remained significantly higher in the intervention group 
even when adjusted for recruitment period, treatment 
group, study centre, age, current sexual relationship, 
previous use of effective contraception, ethnicity, and pre-
viously giving birth, and was robust to the effect of mis-
sing data (table 3) shown by using a multiple imputation 
approach under an assumption of missing at random.
The methods of contraception used by participants at 
4 months after emergency contraception are shown in 
the appendix (p 4). The most commonly used method 
was the progestogen-only pill in the intervention group 
and combined hormonal contraception in the control 
group. None of the women were sterilised or relying on 
a vasectomy. LARC use was not significantly different 
between the intervention group (13 [7%] of 198) and 
control group (23 [11%] of 208, 95% CI –10·04% to 1·05%; 
p=0·112). The most common reason given by women 
Figure 2: Flowchart of participants
N is the number of women recruited, P is the number of pharmacies, and n is the 
number of women providing  follow-up at 4 months.
Washout
Washout
Baseline
Period 1 Period 2
Control
N=161
P=13
n=100
Intervention
N=86
P=11
n=51
Intervention
N=229
P=16
n=147
Control
N=157
P=14
n=108
Intervention 
group, period 1 
(N=229)
Intervention 
group, period 2 
(N=86)
Control group, 
period 1 
(N=161)
Control group, 
period 2 
(N=157)
Age, years
Mean 23·2 (6·0) 21·4 (4·8) 22·2 (4·4) 22·9 (5·8)
Methods of contraception used
Combined hormonal 
contraceptive (pill, patch, or ring)
114 (49·8%) 41 (47·7%) 99 (61·5%) 94 (59·9%)
Progestogen-only pill 39 (17·0%) 19 (22·1%) 35 (21·7%) 32 (20·4%)
Male condom 189 (82·5%) 66 (76·7%) 117 (72·7%) 135 (86·0%)
Progestogen-only injectable 14 (6·1%) 6 (7·0%) 10 (6·2%) 18 (11·5%)
Progestogen-only implant 29 (12·7%) 10 (11·6%) 23 (14·3%) 19 (12·1%)
Copper-bearing intrauterine 
device
6 (2·6%) 0 4 (2·5%) 4 (2·5%)
Levonorgestrel-releasing 
intrauterine system
0 1 (1·2%) 4 (2·5%) 2 (1·3%)
Withdrawal method 65 (28·4%) 28 (32·6%) 52 (32·3%) 67 (42·7%)
Other methods* 10 (4·4%) 6 (7·0%) 7 (4·3%) 9 (5·7%)
Never used any method 8 (3·5%) 4 (4·7%) 10 (6·2%) 2 (1·3%)
Sexual and reproductive history
Previous birth 30 (13·1%) 5 (5·8%) 7 (4·3%) 13 (8·3%)
Previous termination 38 (16·6%) 6 (7·0%) 22 (13·7%) 27 (17·2%)
Previous miscarriage 17 (7·4%) 5 (5·8%) 10 (6·2%) 6 (3·8%)
Current sexual relationship 176 (76·9%) 55 (64·0%) 104 (64·6%) 111 (70·7%)
First time use of emergency 
contraception
52 (22·7%) 22 (25·6%) 28 (17·4%) 32 (20·4%)
Number of times emergency contraception used in past 12 months
Mean 1·4 (1·4) 1·5 (1·5) 1·5 (1·2) 1·7 (2·0)
Median 1·0 (0·0–2·0) 1·0 (1·0–2·0) 1·0 (1·0–2·0) 1·0 (1·0–2·0)
Minimum, maximum 0·0–8·0 0·0–9·0 0·0–6·0 0·0–20·0
Ethnic background
White 157 (68·6%) 60 (69·8%) 98 (60·9%) 114 (72·6%)
Asian or Asian British 21 (9·2%) 6 (7·0%) 8 (5·0%) 21 (13·4%)
Black or Black British 29 (12·7%) 12 (14·0%) 36 (22·4%) 15 (9·6%)
Mixed or other 19 (8·3%) 6 (7·0%) 17 (10·6%) 6 (3·8%)
Not specified 3 (1·3%) 2 (2·3%) 2 (1·2%) 1 (0·6%)
Data are mean (SD), N (%), or median (25th, 75th percentile). N is the number of women recruited. The proportion of 
women with previous history of ectopic pregnancy was less than 1% in all groups. *Other methods of protection were 
female condom, cap or diaphragm, vasectomy, fertility awareness, and emergency contraception.
Table 1: Baseline characteristics
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for not using an effective contraceptive method at 
4 months was that they were not currently sexually active 
(appendix p 5). Significantly fewer women in the 
intervention group (20 [10%]) compared with the control 
group (37 [18%], –15·38% to –1·48%; p=0·018) had 
used emergency contraception again since recruitment 
(appendix p 5). Significantly more women in the 
intervention group (194 [98%] vs 157 [76%]) reported 
that the pharmacist had provided information about 
starting ongoing contraception and where to access it 
(appendix p 6). Of 198 respondents in the intervention 
group, 158 (80%) reported using some of the supplied 
progestogen-only pill. Data on when these participants 
started the progestogen-only pill, number of pill packets 
used, and reasons for non-use or discontinuation are 
shown in the appendix (p 7).
Data from the 4-month follow-up interview on use of 
the rapid access card, contraception supplied, and 
experience at the sexual and reproductive health clinic 
are shown in the appendix (p 8). Most respondents in 
the intervention group (137 [69%] of 198) could recall 
receiving the rapid access card, but only 31 (19%) attended 
the local sexual and reproductive health clinic preferring 
to obtain contraceptive supplies from their general 
practitioner. Only 17 (55%) of those 31 remembered to 
take the rapid access card with them. Of 31 (16%) women 
in the intervention group who attended the sexual 
and reproductive health clinic, only two used the rapid 
access card within 1 month of recruitment. Five of 
31 rapid access card users received a LARC method 
(appendix p 8).
Data obtained from the sexual and reproductive health 
clinic showed that a similar proportion of participants 
in both groups attended the clinics within 4 months 
of recruitment (52 [17%] of 305 in the intervention 
group vs 43 [14%] of 309 in the control group, 95% CI 
–2·60% to 8·87%; p=0·284). Contraception was supplied 
to 41 (43%) of 95 clinic attendees and the methods of 
contraception are shown in the appendix (p 9). The most 
common method supplied to women in the 
intervention group was the progestogen-only pill. A total 
of 75 women attended the sexual and reproductive health 
clinic and provided data at the 4-month follow-up 
interview. In 34 of 75 cases, the sexual and reproductive 
health clinic provided a contraceptive method. Of 
these 34, 30 (88%) women reported using the same 
method of contraception at 4 months as the method 
provided by the sexual and reproductive health clinic.
A total of 19 (4·7%) respondents (nine in the 
intervention and ten in the control group) reported that 
they had been pregnant (17) or were currently 
pregnant (two) since recruitment. In ten of 19 cases the 
pregnancy ended in abortion, six women miscarried, and 
the outcome of one pregnancy was unknown. Based on 
scores from the London Measure of Unplanned 
Pregnancy question naire,15,16 seven of nine pregnancies 
in the intervention group and eight of ten in the control 
group were clearly unintended.
Discussion
The Bridge-It study showed that this simple pharmacist-
delivered intervention, in which a bridging supply of the 
progestogen-only pill was given to women requesting 
emergency contraception along with the offer of rapid 
access to a sexual and reproductive health clinic, resulted 
in a significantly higher proportion of women using 
an effective method of contraception 4 months later 
compared with when emergency contraception was 
supplied alone. The difference in uptake of effective 
contraception between groups was large and likely to be 
clinically meaningful. Additionally, significantly fewer 
Intervention 
group
Control 
group
Estimate* 
(95% CI)
p value
Primary 
outcome†
21; 58·4% 
(21·6)
21; 40·5% 
(23·8)
20·1% 
(5·2–35·0)
0·011
Primary outcome 
adjusted‡
21; 58·4% 
(21·6)
21; 40·5% 
(23·8)
14·5% 
(0·9–28·2)
0·038
Primary outcome 
adjusted with 
additional 
covariates§
21; 58·4% 
(21·6)
21; 40·5% 
(23·8)
18·5% 
(1·4–35·6)
0·036
Data are N; mean (SD), unless otherwise specified. N is the number of 
pharmacies. Outcome is the percentage of effective contraception uptake at 
4 months follow-up. *The estimated treatment effect (percentage difference 
between groups) in proportion with the outcome. †Adjusted for phase, 
treatment group, and centre. ‡Adjusted for phase, treatment group, centre, 
mean age, percentage of participants in a current sexual relationship, and 
percentage of participants who had used effective contraception previously. 
§Post-hoc analysis adjusted in addition to the prespecified baseline covariates for 
ethnicity and having given birth previously. 
Table 2: Primary analysis for cluster-level models
Intervention 
group
Control group Estimate* (95% CI) p value
Cluster-level models†
Omit cluster with <3 responses 14; 60·2% (19·7) 14; 42·9% (13·8) 15·2% (2·3 to 28·1) 0·026
Omit cluster with 
>30% individuals missing data 
(excluding centre)
5; 58·5% (14·4) 5; 44·1% (6·6) 14·7% (1·1 to 28·2) 0·040
Including percentage missing 
and number of responders
21; 58·4% (21·6) 21; 40·5% (23·8) 15·3% (–0·1 to 30·6) 0·051
Including percentage missing 21; 58·4% (21·6) 21; 40·5% (23·8) 15·0% (0·3 to 29·7) 0·046
Including number of 
responders
21; 58·4% (21·6) 21; 40·5% (23·8) 15·0% (0·6 to 29·4) 0·042
Multiple imputation ·· ·· 15·0% (–2·0 to 32·0) 0·076
Hierarchical models‡
Fixed effects for cluster 
(n=397)
112/198 (56·6%) 85/208 (40·9%) 1·93%§ (1·21 to 3·09) 0·0058
Data are N; mean (SD), or n/N (%), unless otherwise specified. N is the number of pharmacies. *The estimated 
treatment effect (percentage difference between groups) in proportion with the outcome. †Outcome is the 
percentage of effective contraception uptake and analyses were adjusted for phase, treatment group, centre, mean 
age, percentage of participants who were in a current sexual relationship, and percentage of participants who had used 
effective contraception previously. ‡Outcome is the uptake of effective contraception (binary) and was adjusted for 
phase, treatment group, and centre. §Odds ratio.
Table 3: Sensitivity analysis
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women in the interven tion group used emergency 
contraception again, during these 4 months.
Aside from our pilot study,9 to our knowledge, this is 
the only published study designed to encourage uptake 
of effec tive contraception after emergency contraception 
offered women in Jamaica a time-limited discount for 
the cost of contraceptive pills, but the intervention had 
no effect on subsequent contraceptive use.19 Another 
intervention that has shown a clinical effect on the 
uptake of effective contraception is the CHOICE project 
from the USA.20 In this study,20 over 9000 women 
requiring regular contraception were counselled about 
LARC and provided with their chosen method free of 
charge in a setting in which contraception is usually not 
free (and LARC is expen sive). The CHOICE project 
reported that LARC uptake was 67% compared with the 
national rate of 3% in the USA. By contrast, in the 
Bridge-it study, we assessed an inter vention in a 
pharmacy setting at request for emergency contraception. 
This intervention was simpler to deliver and more 
affordable.
The Bridge-it study was a well-designed trial with an 
appropriate sample size to show the expected effect with 
sufficient power. This pragmatic trial had few inclusion 
and exclusion criteria,21 and included a mix of large 
chain and small independent pharmacies that dispensed 
emergency contraception at a high volume, so the results 
are probably generalisable to UK pharmacies in which 
most emergency contraception is provided. The study 
design was shaped by learning from the pilot study9 and 
this larger trial confirmed the pilot study findings in a 
more generalised setting. The findings were robust and 
remained highly statistically significant after adjustment 
for a range of relevant factors and for missing data. 
Women who participated in this study had similar 
characteristics to emergency contraception users nation-
ally, suggesting that they are representative of women in 
the UK seeking emergency contraception to avoid an 
unintended pregnancy.9,22
One of the challenges when conducting this study was 
that pharmacists are typically unfamiliar with partici-
pating in research.23 Dispensing emergency contraception 
can be time-intensive and, thus, asking pharmacists to 
recruit participants, provide further information, and 
complete additional paperwork as part of a research 
study was an added burden. Consequently, recruitment 
took longer than anticipated and there were large 
differences between pharmacies in the number of 
women recruited and within pharmacies in the number 
recruited in each period.
As expected, there was a substantial drop-out rate 
for the self-reported primary outcome of effective 
contraception use at 4 months. We had estimated this 
loss to be at 25% and in the trial it was 35%. However, 
there was no differential loss to follow-up either between 
treatment groups or between recruitment periods. We 
checked the robustness of our findings to the effect of 
these missing data using a multiple imputation approach 
under an assumption of missing at random and the 
findings were confirmed. In addition, the characteristics 
of participants who did and did not provide follow-up 
data were similar. Although from a methodological 
perspective it would have been ideal for every pharmacy 
to have contributed an equal number of participants in 
both periods, for a pragmatic trial and to make the 
findings relevant to routine practice, we enlisted a range 
of pharmacy sizes with differing numbers of pharmacists 
(from single-handed to multiple pharmacist stores). The 
cohort design meant that different groups of women 
would participate in the two periods. All these factors 
contributed to varying recruitment rates across phar-
macies and between periods, resulting in different 
lengths of required recruit ment. Although this design 
was more difficult to manage, it produced more robust 
and generalisable findings than randomisation at an 
individual participant level.
Pregnancy was not the primary endpoint in this study. 
Although we still plan to record linkage with abortion 
statistics 12 months after emergency contraception use 
(number of births anticipated to be few and the relevant 
time frame for follow-up anticipated to be longer), this 
study was underpowered for this comparison. Use of 
effective contraception should prevent unintended preg-
nancy and is used as a surrogate measure in contracep-
tive research studies. The effectiveness of contraception 
is dependent on continuity and correct use; however, 
discontinuation24 and incorrect use25 are common. 
Longer follow-up was not possible in this study but 
would have provided data on continuation of the chosen 
method. Contraceptive use was self-reported and pub-
lished evidence shows that women’s self-reporting of the 
contraceptive method is reasonably reliable.26 Enthusiasm 
among study pharmacists could have resulted in a higher 
than usual proportion of women in the control group 
receiving advice about the importance of ongoing 
contraception than under non-study conditions. Notably, 
three-quarters of women in the control group of the 
Bridge-it trial received advice about contraception 
compared with a half of women in the mystery shopper 
study designed to characterise standard care.12
An important factor for effective contraceptive use 
in the intervention group was continued use of the 
progestogen-only pill, as more women in the intervention 
group than in the control group requested further 
supplies of the progestogen-only pill from sexual and 
reproductive health clinics and their general prac titioner. 
In the pilot study and this trial, the progestogen-only pill 
was the subsequent method of choice for a large 
proportion of women, even at sexual and reproductive 
health clinics with the full range of methods available.9 
The progestogen-only pill has not been a common first 
choice among women in the UK; it is estimated to be 
used by only 5·6% of prescription contraceptive users,27 
and is usually reserved for those with contraindications 
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to the combined oral contraceptive pill.28 Perhaps, the 
progestogen-only pill is not widely offered to women by 
providers, but when given the option, women decide to 
continue use, as observed in this trial.
The intervention could also have served as a reminder 
to the pharmacist to discuss contraception, given that 
more women in the intervention group than in the 
control group received advice about ongoing contra-
ception. In our earlier pilot study women were given only 
a 1-month supply of the progestogen-only pill.9 Our 
hypothesis for the pilot study was that around the time of 
seeking emergency contraception, women might be 
highly motivated to arrange a visit to their contraceptive 
provider to obtain ongoing contraception and receiving a 
1-month supply of the progestogen-only pill gave them 
sufficient time to arrange a visit. We were concerned that 
a 3-month supply of the progestogen-only pill would be 
too much, as motivation to seek ongoing contraception 
might dissipate with time, but findings from the Bridge-it 
study showed otherwise.
The rapid access card to a sexual and reproductive 
health clinic was used by fewer than one in five women 
(compared with 32% in the earlier pilot study),9 and only 
two women (1% of the total intervention) used this access 
card rapidly (within 1 month). Also, the rapid access card 
did not result in more women using the sexual and 
reproductive health clinic compared with the control 
group. The rapid access component was intended to 
facilitate access to LARC but only 16% of rapid access 
card users received LARC. Although we cannot conclude 
that the rapid access does not make a meaningful 
contribution to accessing effective contraception for 
some, the findings suggest that this component might be 
less important than the bridging progestogen-only pill 
intervention.
Despite free contraceptive services in the UK, unin-
tended pregnancy remains a public health problem.29 
In 2018 there were 200 608 induced abortions for women 
in England and Wales and 13 286 in Scotland.30,31 In 
England and Wales this number represented an increase 
of 4% since 2017 and the highest number recorded, 
whereas the figures for Scotland represent a 10-year 
high. What would happen if offering 3-months’ supply of 
the progestogen-only pill with emergency contraception 
became standard practice throughout the UK? An 
increase of 20% in contraceptive uptake is large and 
clinically significant. Additionally, pharmacy provision of 
an oral contraceptive is inexpensive. A 3-month supply of 
the desogestrel progestogen-only pill costs the NHS £2·97 
and the reimbursed cost of the pharmacist’s time is 
likely to be around £30.32,33 If this approach was routinely 
implemented as a service without the need to participate in 
a research study, many more women might accept the offer 
of the progestogen-only pill with emergency contraception. 
A survey conducted in 2013, involving over 100 women 
seeking emergency contraception from pharmacies in 
Edinburgh, showed that two-thirds of women welcomed 
the prospect of receiving a bridging supply of the 
progestogen-only pill along with emergency contra-
ception.22 This bridging method has also received support 
from members of the Faculty of Sexual and Reproductive 
Healthcare UK, gathered from surveys.22,34 The progestogen-
only pill is safe and has few contra indications to use.28 In 
addition, current threats of the pan demic to health-care 
delivery show the importance of developing alternative 
methods for supplying contraception.
In addition to increasing uptake of effective contra-
ception, it is hoped that implementing bridging widely 
could reduce the rates of repeat use of emergency 
contraception, particularly among those who are most at 
risk of an unintended pregnancy. This point is particularly 
important, as findings from the British National Survey 
of Sexual Attitudes and Lifestyles (NATSAL-3),29 done 
between 2010 and 2012, highlight that emergency 
contraception users represent a group of women at 
greater risk of unintended pregnancy, and that use of 
emergency contraception has risen in this group.6 Thus, 
it is unsurprising that the pregnancy rate at 4·7% shown 
in the Bridge-it study in the first 4 months of follow-up 
seems considerable. NATSAL-3 also found that use of 
emergency contraception had increased among single 
women, those living in less affluent areas, and those 
obtaining emergency contra ception from retail rather 
than health-care sources.6 This finding highlights the 
potential for providing bridging contraception within 
retail settings, such as community pharmacies, to reduce 
repeat emergency contracep tion use and unintended 
pregnancies in this group.35 Importantly, the mean age of 
women participating in the Bridge-it study was 22 years, 
highlighting that the intervention reached key age 
groups; abortion rates in the UK are highest among 
women aged 20–24 years30,31 and use of emergency 
contraception highest among women aged 16–24 years.6 
Thus, if the Bridge-it inter vention were implemented 
widely as a service, the use of effective contraception 
might increase in the relevant age group and among 
those at greater risk of unintended pregnancy.
Some might argue that our intervention could under-
mine attempts to encourage use of LARC. However, there 
were no significant differences between the two groups in 
this study in the uptake of LARC after emergency 
contraception use. It was disappointing that few women 
in the intervention group used the rapid access card 
which gave priority access to sexual and reproductive 
health services offering LARC. Data from interviews with 
participants, pharmacists, and sexual and reproductive 
health clinic staff, done as part of the evaluation (to be 
published separately), will provide more understanding. 
However, there are many women who do not want to use 
LARC,36 and they might be more likely to present for 
emergency contraception. Modelling from the USA37 
has shown that a greater proportion of unintended 
pregnancies at population level could be prevented if 
efforts focused on encouraging sexually active women 
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who are not using an effective contra ceptive method 
(eg, progestogen-only pill) rather than switching those 
already using an effective method to a more effective 
LARC method.
We chose to provide the progestogen-only pill as 
bridging contraception rather than the more commonly 
used combined oral contraceptive pill, because the pro-
gestogen-only pill has fewer contraindications and health 
risks.38 The progestogen-only pill (75 μg desogestrel per 
day) consistently inhibits ovulation in almost all users 
(by contrast with the first-generation progestogen-only 
pills), and can be missed for 12 h without jeopardising 
effectiveness,28 and so is likely to be as effective as the 
combined oral contraceptive. The progestogen-only pill 
might also be easier to use because it is taken every day 
without a break.
Our study involved levonorgestrel-containing emergency 
contraception, which was the most common emer gency 
contraception used at the time,39 and is suitable for 
immediate start of hormonal contraception.4 However, 
another oral emergency contraception, ulipristal acetate, 
has been shown to be more effective and is now widely 
available from UK community pharmacies.40 Future rollout 
of this intervention does not need to be limited to 
levonorgestrel-containing emergency contraception and 
can be adapted for other methods. The progestogen-only 
pill could be provided alongside ulipristal acetate with the 
recommendation to wait 5 days before starting the 
progestogen-only pill, to avoid a possible negative effect of 
the contraception on the effectiveness of ulipristal acetate, 
given that ulipristal is a progesterone receptor modulator.4
The Bridge-it study provides robust evidence that 
provision of a bridging supply of the progestogen-only 
pill with emergency contraception from a community 
pharmacy, together with an invitation to a sexual and 
reproductive health clinic, result in a clinically important 
increase in continued effective contraception use com-
pared with provision of emergency contraception alone. 
Widescale implementation of this simple and safe 
intervention is now indicated and should be expected to 
reduce the rates of unintended pregnancy after emer-
gency contraception.
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